Cell Type | n per Group | Melatonin | Tamoxifen | 4-OH- Tamoxifen | Melatonin + Tamoxifen | Melatonin + 4-OH-Tamoxifen | C2 | C4 | C5 | C9 | C15 |
---|---|---|---|---|---|---|---|---|---|---|---|
MCF-7 | |||||||||||
Viability | 4 | 18 ± 18 nM | 12 ± 20 mM | 34 ± 41 mM | 328 ± 222 µM | 17 ± 29 mM | 69 ± 81 mM | 4 ± 4.31 nM | 440 ± 331 mM | 107 ± 17 mM abcde | 34 ± 15 µM |
Migration | 4 | 309 ± 164 nM | 138 ± 117 µM | 13 ± 13 mM | 11 ± 0.1 nM | 131 ± 18 mM abc | 100 ± 156 µM e | 9 ± 11 mM e | 4 ± 3.3 µM e | 218 ± 48 mM abce | 1 ± 2 µM e |
MMC | |||||||||||
Viability | 4 | 427 ± 479 nM | 3 ± 3.1 µM | 4 ± 1.5 µM | 3 ± 2 µM | 7 ± 2.3 µM a | 13 ± 8 µM abcde | 243 ± 331 nM e | 6 ± 1.6 µM | 6 ± 2.8 µM | 333 ± 333 mM |
Migration | 4 | 231 ± 392 nM | 21 ± 23 µM | 3 ± 3.6 µM | 31 ± 40 µM | 68 ± 33 µM ac | 221 ± 65 mM abcde | 5 ± 8 mM | 227 ± 200 nM e | 206 ± 25.7 µM abcde | 110 ± 149 nM |
MDA-MB-231 | |||||||||||
Viability | 4 | 52 ± 89 nM | 58 ± 67 mM | 26 ± 30 µM | 419 ± 354 mM | 69 ± 106 nM | 246 ± 178 µM | 37 ± 34 nM | 12 ± 11 µM d | 145 ± 70 mM | 477 ± 674 pM |
Migration | 4 | 123 ± 239 µM | 30 ± 35 mM | 91 ± 84 µM | 229 ± 232 mM | 5 ± 3 µM | 559 ± 131 mM abcde | 11 ± 19 mM d | 3 ± 3 µM | 269 ± 119 µM | 173 ± 157 mM |
BT-549 | |||||||||||
Viability | 3 | 504 ± 0.1 nM | 781 ± 7 mM | 30 ± 0.9 µM | 11 ± 19 mM | 24 ± 11 µM a | 24 ± 8 µM b | 6 ± 2 µM b | 24 ± 31 µM b | 34 ± 34 µM b | 2 ± 3 µM b |
Migration | 4 | 4 ± 6 µM | 11 ± 18 µM | 3 ± 3 µM | 24 ± 7 µM | 116 ± 93 µM | 579 ± 308 mM abcde | 9 ± 9 µM | 51 ± 62 µM | 328 ± 340 mM | 18 ± 23 nM |
Data were analyzed by one-way ANOVA followed by the Newman–Keuls post hoc t test where significance was defined as P < 0.05. Letters denote significance between groups as follows: a, P < 0.05 vs. melatonin; b, P < 0.05 vs. tamoxifen; c, P < 0.05 vs. 4-OH- tamoxifen; d, P < 0.05 vs. melatonin + tamoxifen; and e, P < 0.05 vs. melatonin + 4-OH- tamoxifen.